Silence Therapeutics plc (SLNCF)
SLNCF Stock Price Chart
Explore Silence Therapeutics plc interactive price chart. Choose custom timeframes to analyze SLNCF price movements and trends.
SLNCF Company Profile
Discover essential business fundamentals and corporate details for Silence Therapeutics plc (SLNCF) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
25 Sept 2012
Employees
116.00
CEO
Craig A. Tooman
Description
Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development of novel ribonucleic acid (RNA) therapeutics in hematology, cardiovascular, and other rare and metabolic indications. The company's platform includes mRNAi GalNAc Oligonucleotide Discovery platform designed to accurately target specific disease-associated genes in the liver. It designs short interfering RNA molecules to harness the body's natural mechanism of RNA interference, and degrading messenger RNA molecules that encode specific targeted disease-associated proteins in a cell. The company is developing various product candidates, including SLN360, which is Phase I clinical trials for the treatment of cardiovascular disease with high lipoprotein; SLN124 that is in Phase I clinical trials for the treatment of non-transfusion dependent thalassemia, and Phase I clinical trials for the treatment of myelodysplastic syndrome; and SLN124 for the treatment of polycythemia vera. It has collaboration agreements with AstraZeneca PLC to discover, develop, and commercialize small interfering RNA therapeutics for the treatment of cardiovascular, renal, metabolic, and respiratory diseases; and Mallinckrodt Pharma IP Trading DAC to develop and commercialize RNAi drug targets designed to silence the complement cascade in complement-mediated disorders. The company also has a collaboration with Hansoh Pharmaceutical Group Company Limited to develop siRNAs for three undisclosed targets leveraging Silence's mRNAi GOLD platform. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc is headquartered in London, the United Kingdom.
SLNCF Financial Timeline
Browse a chronological timeline of Silence Therapeutics plc corporate events including earnings releases, dividend announcements, and stock splits.
Earnings released on 7 Aug 2025
EPS came in at -$0.26 falling short of the estimated -$0.04 by -490.70%, while revenue for the quarter reached $307.20K , missing expectations by -95.67%.
Earnings released on 8 May 2025
EPS came in at -$0.26 falling short of the estimated -$0.05 by -411.12%, while revenue for the quarter reached $183.71K , missing expectations by -92.09%.
Earnings released on 27 Feb 2025
EPS came in at $0.13 surpassing the estimated -$0.07 by +281.17%, while revenue for the quarter reached $30.44M , beating expectations by +349.63%.
Earnings released on 14 Nov 2024
EPS came in at -$0.25 falling short of the estimated -$0.04 by -476.53%, while revenue for the quarter reached $1.50M , missing expectations by -74.43%.
Earnings released on 15 Aug 2024
EPS came in at -$0.14 falling short of the estimated -$0.04 by -273.82%, while revenue for the quarter reached $756.89K , missing expectations by -93.51%.
Earnings released on 31 Mar 2024
EPS came in at -$0.02 surpassing the estimated -$0.04 by +55.73%, while revenue for the quarter reached $15.57M , beating expectations by +145.09%.
Earnings released on 13 Mar 2024
EPS came in at -$0.16 falling short of the estimated -$0.03 by -506.61%, while revenue for the quarter reached $2.65M , missing expectations by -70.36%.
Earnings released on 30 Sept 2023
EPS came in at -$0.09 falling short of the estimated -$0.06 by -59.68%, while revenue for the quarter reached $3.40M , beating expectations by +16.26%.
Earnings released on 30 Jun 2023
EPS came in at -$0.12 falling short of the estimated -$0.06 by -107.82%, while revenue for the quarter reached $11.53M , beating expectations by +197.79%.
Earnings released on 31 Mar 2023
EPS came in at -$0.12 falling short of the estimated -$0.05 by -138.27%, while revenue for the quarter reached $14.06M , beating expectations by +355.98%.
Earnings released on 15 Mar 2023
EPS came in at -$0.18 falling short of the estimated -$0.01 by -3.12K%, while revenue for the quarter reached $5.86M , missing expectations by -71.09%.
Earnings released on 30 Sept 2022
EPS came in at -$0.08 falling short of the estimated -$0.06 by -32.08%, while revenue for the quarter reached $3.73M .
Earnings released on 30 Jun 2022
EPS came in at -$0.16 falling short of the estimated -$0.06 by -151.79%, while revenue for the quarter reached $4.42M .
Earnings released on 31 Mar 2022
EPS came in at -$0.11 falling short of the estimated -$0.06 by -76.90%, while revenue for the quarter reached $7.50M .
Earnings released on 17 Mar 2022
EPS came in at -$0.14 surpassing the estimated -$0.42 by +65.86%, while revenue for the quarter reached $4.61M , missing expectations by -49.32%.
Earnings released on 30 Sept 2021
EPS came in at -$0.15 , while revenue for the quarter reached $4.26M .
Earnings released on 30 Jun 2021
EPS came in at -$0.18 , while revenue for the quarter reached $3.73M .
Earnings released on 31 Mar 2021
EPS came in at -$0.13 , while revenue for the quarter reached $4.34M .
Earnings released on 30 Mar 2021
EPS came in at -$0.03 , while revenue for the quarter reached -$1.15M .
Earnings released on 30 Sept 2020
EPS came in at -$0.14 , while revenue for the quarter reached $2.57M .
SLNCF Stock Performance
Access detailed SLNCF performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.